Progress in Understanding Basal Ganglia Dysfunction as a Common Target for Methamphetamine Abuse and HIV-1 Neurodegeneration

Author(s): Shaji Theodore, Wayne A. Cass, Avindra Nath, William F. Maragos

Journal Name: Current HIV Research

Volume 5 , Issue 3 , 2007

Become EABM
Become Reviewer


HIV-1 infection with concurrent methamphetamine (MA) abuse results in exacerbated neurodegenerative changes and rapid progression of a form of sub-cortical dementia termed HIV-1 associated dementia (HAD). A notable feature of HAD is the involvement of the dopaminergic system manifested as parkinsonian like movement abnormalities. The HIV-1 transactivator of transcription (Tat) protein is very often used in experimental studies trying to understand neurotoxic consequences of HIV-1 infection, since the pathophysiological changes induced by Tat mirrors, in part, the means by which HIV-1 infection of the nervous system results in neuronal damage. Understanding the interaction of Tat and MA in the basal ganglia and the resultant injury to the dopaminergic system in rodent models as well as cell culture will shed light on the dopaminergic pathology occurring in HIV-1 infected-MA abusers. The aim of this review is to update the reader on the current knowledge of MA and HIV-1 neurotoxicity, specifically Tat, and discuss the progress in understanding how MA synergizes with the HIV-1 transactivator protein Tat to damage the basal ganglia.

Keywords: Drug abuse, AIDS, glia, cytokines, dopamine, striatum, neurodegeneration

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [301 - 313]
Pages: 13
DOI: 10.2174/157016207780636515
Price: $65

Article Metrics

PDF: 5